Navigation Links
Genetic key to growth of new arteries is identified

Researchers at the San Francisco VA Medical Center have uncovered part of the genetic mechanism that causes new arteries to grow in response to blocked arteries.

A team led by SFVAMC vascular surgeon Rajabrata Sarkar, MD, PhD, has demonstrated in mice that the MMP2 gene is essential for the growth of new arteries when the femoral (leg) artery is blocked.

The team also identified and described, for the first time, the specific DNA sequences of the MMP2 gene that are expressed when new arteries are grown.

The study appears in the November 8 issue of the Proceedings of the National Academy of Sciences.

"It is not clear why some patients grow new arteries in response to an arterial blockage and others do not," observes Sarkar, who is also an assistant professor of surgery at the University of California, San Francisco. "So it's very important to understand the normal process that allows an animal or a person to grow new arteries when their legs don't get good blood flow. Legs are a big problem, because if you don't have enough blood flow, it can eventually lead to gangrene and amputation."

In the first part of the study, Sarkar and his group mimicked human vascular disease in the femoral arteries of normal mice and of mice that lacked the MMP2 gene, which encodes an enzyme that promotes the growth of new arteries.

The normal mice grew new arteries, and in about three weeks the blood flow in their legs was close to normal.

The mice without the MMP2 gene did not grow new arteries. About 40 percent lost a portion of a leg due to gangrene caused by inadequate blood flow, demonstrating that the MMP2 gene is "very important" in an animal's ability to grow new arteries in response to a blockage, says Sarkar.

The second part of the study looked at precisely which areas of the MMP2 gene are activated in skeletal muscles where blood flow is decreased.

The researchers mimicked arterial blockage in transgenic mice created by David Lovett, MD, chief of nephrology at SFVAMC, professor in residence of medicine at UCSF, and one of the co-authors of the study.

The mice carried a marker gene, beta galactosidase, that turns tissues blue. Different strains of the mice had different fragments of the MMP2 gene coupled to the so-called blue gene. Leg muscles turned blue only in the strain of mice with the specific gene fragment that turns on in response to arterial blockage.

In this way, the researchers identified and described previously unknown areas of the MMP2 gene, plus other molecules that activate those areas, that are essential to expression of the gene in response to decreased blood flow.

"It's a very time-consuming approach, but a very elegant way to deal with the problem," comments Sarkar. "This paper is a very fundamental examination of the mechanisms involved in gene regulation in the growth of arteries." The next research step, according to Sarkar, will be to carry out the same experiments in animal models of the various conditions known to cause vascular disease: cigarette smoking, high cholesterol, diabetes, and hypertension.

"For each of these models we will ask, one, is expression of MMP2 impaired, and two, if there is less arterial growth," Sarkar says. "Then if both of those are true ?and we think they will be ?then we can identify the mechanisms by which expression of MMP2 is blocked."

Over the long term, Sarkar plans to study the same genetic mechanisms in humans, "perhaps in tissue samples taken from patients at the time of surgery." He hopes that eventually, his research will lead to new clinical treatments for arterial blockage in patients.

"As a vascular surgeon, I take care of people who have problems with poor blood flow to different parts of their bodies," he notes. "One thing we know for sure: our patients do not grow new arteries, and that's why I have to operate on them."

Other co-authors o f the study were Jackie G. Lee, BS; Sia Dahi, BS; Rajeev Mahimkar, PhD; Nathaniel L. Tulloch, BS; and Maria A. Alfonso-Jaume, MD, all of SFVAMC.


'"/>

Source:University of California - San Francisco


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Genetically modified natural killer immune cells attack, kill leukemia cells
3. Ants Genetic Engineering Leads To Species Interdependency
4. Genetic Variation Visualization - From EMBL
5. Genetically modified rice in China benefits farmers health, study finds
6. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
7. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
8. Genetic defects give the immune system the green light to attack the pancreas
9. Maine Researchers Find Exceptions to Old Rules of Genetic Inheritance
10. Genetic therapy reverses nervous system damage in animal model of inherited human disease
11. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... BOSTON , Jan. 20, 2017 ... acquisition of Gen9, a pioneer in the synthesis ... Gen9,s unique expertise in assembling pathway-length synthetic DNA ... speed and capacity in the construction of new ... of industries. "Gen9 was founded to ...
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... 19, 2017 , ... FireflySci Inc. is a go-getter type of company that ... accounted to two main factors. The first is the amazing customer service that ... FireflySci products all around the world. , 2016 was a tremendous sales year for ...
Breaking Biology Technology: